Unknown

Dataset Information

0

BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.


ABSTRACT: Introduction: BRM, a key catalytic subunit of the SWI/SNF chromatin remodeling complex, is a putative tumor susceptibility gene that is silenced in 15% of non-small cell lung cancer (NSCLC). Two novel BRM promoter polymorphisms (BRM-741 and BRM-1321) are associated with reversible epigenetic silencing of BRM protein expression.Experimental Design: Advanced NSCLC patients from the Princess Margaret (PM) cohort study and from the CCTG BR.24 clinical trial were genotyped for BRM promoter polymorphisms. Associations of BRM variants with survival were assessed using log-rank tests, the method of Kaplan and Meier, and Cox proportional hazards models. Promoter swap, luciferase assays, and chromatin immunoprecipitation (ChIP) experiments evaluated polymorphism function. In silico analysis of publicly available gene expression datasets with outcome were performed.Results: Carrying the homozygous variants of both polymorphisms ("double homozygotes", DH) when compared with those carrying the double wild-type was associated with worse overall survival, with an adjusted hazard ratios (aHR) of 2.74 (95% CI, 1.9-4.0). This was confirmed in the BR.24 trial (aHR, 8.97; 95% CI, 3.3-18.5). Lower BRM gene expression (by RNA-Seq or microarray) was associated with worse outcome (P < 0.04). ChIP and promoter swap experiments confirmed binding of MEF2D and HDAC9 only to homozygotes of each polymorphism, associated with reduced promoter activity in the DH.Conclusions: Epigenetic regulatory molecules bind to two BRM promoter sequence variants but not to their wild-type sequences. These variants are associated with adverse overall and progression-free survival. Decreased BRM gene expression, seen with these variants, is also associated with worse overall survival. Clin Cancer Res; 23(10); 2460-70. ©2016 AACR.

SUBMITTER: Liu G 

PROVIDER: S-EPMC5422138 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.

Liu Geoffrey G   Cuffe Sinead S   Liang Shermi S   Azad Abul Kalam AK   Cheng Lu L   Brhane Yonathan Y   Qiu Xin X   Cescon David W DW   Bruce Jeffrey J   Chen Zhuo Z   Cheng Dangxiao D   Patel Devalben D   Tse Brandon C BC   Laurie Scott A SA   Goss Glenwood G   Leighl Natasha B NB   Hung Rayjean R   Bradbury Penelope A PA   Seymour Lesley L   Shepherd Frances A FA   Tsao Ming Sound MS   Chen Bingshu E BE   Xu Wei W   Reisman David N DN  

Clinical cancer research : an official journal of the American Association for Cancer Research 20161108 10


<b>Introduction:</b> BRM, a key catalytic subunit of the SWI/SNF chromatin remodeling complex, is a putative tumor susceptibility gene that is silenced in 15% of non-small cell lung cancer (NSCLC). Two novel <i>BRM</i> promoter polymorphisms (<i>BRM</i>-741 and <i>BRM</i>-1321) are associated with reversible epigenetic silencing of BRM protein expression.<b>Experimental Design:</b> Advanced NSCLC patients from the Princess Margaret (PM) cohort study and from the CCTG BR.24 clinical trial were ge  ...[more]

Similar Datasets

| S-EPMC5978248 | biostudies-literature
| S-EPMC5438633 | biostudies-literature
2021-01-19 | GSE156914 | GEO
| S-EPMC3987092 | biostudies-literature
| 2286534 | ecrin-mdr-crc